Briefly, Farsi and colleagues [27] demonstrated that CoQ10 supplementation in patients with NAFLD limits liver damage by lowering the actions of AST and gamma-glutamyl transpeptidase, in connection with reducing the levels of CRP and TNF-α. Here, CRP is linked to metabolic dysfunction-associated steatotic liver disease.